Company registration number 02826793 (England and Wales)
PRESTIGE MEDICAL LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PRESTIGE MEDICAL LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 11
PRESTIGE MEDICAL LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
4
1,179
2,540
Tangible fixed assets
5
448,487
404,029
Deferred tax asset
11
312,780
312,780
762,446
719,349
Current assets
Stocks
6
714,522
785,594
Debtors
7
787,910
444,269
Cash at bank and in hand
93,156
94,090
1,595,588
1,323,953
Creditors: amounts falling due within one year
8
(3,419,090)
(3,088,993)
Net current liabilities
(1,823,502)
(1,765,040)
Total assets less current liabilities
(1,061,056)
(1,045,691)
Creditors: amounts falling due after more than one year
8
(322,201)
(305,346)
Net liabilities
(1,383,257)
(1,351,037)
Capital and reserves
Called up share capital
13
6,500,002
6,500,002
Profit and loss reserves
(7,883,259)
(7,851,039)
Total equity
(1,383,257)
(1,351,037)
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.
The financial statements were approved by the board of directors and authorised for issue on 29 September 2025 and are signed on its behalf by:
J S Potter
Director
Company registration number 02826793 (England and Wales)
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information
Prestige Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is East House, Duttons Way, Shadworth Business Park, Blackburn, BB1 2QR.
1.1
Accounting convention
The financial statements have been prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework (FRS 101) and in accordance with applicable accounting standards.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
As permitted by FRS 101, the company has taken advantage of the following disclosure exemptions from the requirements of IFRS:
presentation of a statement of cash flows and related notes;
disclosure of the categories of financial instrument and the nature and extent of risks arising on these financial instruments;
the effect of financial instruments on the statement of comprehensive income;
comparative period reconciliations for the number of shares outstanding and the carrying amounts of property, plant and equipment, intangible assets, investment property and biological assets;
disclosure of the future impact of new International Financial Reporting Standards in issue but not yet effective at the reporting date;
related party disclosures for transactions with the parent or wholly owned members of the group.
The financial statements of the company are consolidated in the group accounts of Tuttnauer Limited. The group accounts of Tuttnauer Limited are available to the public and are available from its registered office.
1.2
Going concern
The company is reliant upon support from its trueparent and group companies. The directors have, at the time of approving the financial statements, a reasonable expectation that the company has adequate resources, supported by its parent company, to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
In arriving at this assessment the directors have obtained assurance from its parent company that support will continue to be provided as is appropriate by the parent and group and that no support provided to date by the parent and group will be withdrawn.
Although the company is showing a net liability and net current liability position as at 31 December 2024. £2,487,964 (2023 - £2,003,091) of the company's liabilities are owed to group companies, and are not subject to fixed repayment schedules. The company is fully owned by the Tuttnauer Group, which continues to support the company.
In light of the above the directors consider that there are no material uncertainties that lead to a significant doubt upon the company's ability to continue as a going concern. The directors have relied on the ongoing support of the parent group in making their assessment.
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 3 -
1.3
Turnover
Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reasonably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
The company does not expect to have any contracts where the period between the transfer of the promised good or services to the customer and payment by the customer exceeds one year. As a consequence, the company does not adjust any of the transaction prices for the time value of money.
Turnover from providing services is recognised in the accounting period in which the services are rendered.
Revenue of a standalone service is recognised at a point in time when the service is completed.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
1.4
Intangible assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Software: 3 to 5 years
Website: 3 years
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Right-of-use leasehold property
10 years
Right-of-use other assets
5 to 7 years
Plant and equipment
3 to 15 years
Right-of-use motor vehicles
3 years
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
1.6
Impairment of tangible and intangible assets
At each reporting end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.7
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit and loss. Reversals of impairment losses are also recognised in profit or loss.
1.8
Cash at bank and in hand
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
1.9
Financial assets
Financial assets are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.
At initial recognition, financial assets classified as fair value through profit and loss are measured at fair value and any transaction costs are recognised in profit or loss. Financial assets not classified as fair value through profit and loss are initially measured at fair value plus transaction costs.
Financial assets held at amortised cost
Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (eg trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary. Financial assets classified as receivable within one year are not amortised.
1.10
Financial liabilities
The company recognises financial debt when the company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either 'financial liabilities at fair value through profit or loss' or 'other financial liabilities'.
Other financial liabilities
Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding. Financial liabilities classified as payable within one year are not amortised.
1.11
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 6 -
1.12
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of inventories or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
1.13
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.14
Leases
At inception, the company assesses whether a contract is, or contains, a lease within the scope of IFRS 16. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Where a tangible asset is acquired through a lease, the company recognises a right-of-use asset and a lease liability at the lease commencement date. Right-of-use assets are included within tangible fixed assets, apart from those that meet the definition of investment property.
The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the commencement date plus any initial direct costs and an estimate of the cost of obligations to dismantle, remove, refurbish or restore the underlying asset and the site on which it is located, less any lease incentives received.
The right-of-use asset is subsequently adjusted for remeasurements of the lease liability and applies the relevant cost model, fair value model or revaluation model as set out within the accounting policies for the applicable asset class. Where the cost model is applied, the asset is depreciated from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, and is periodically reduced by impairment losses, if any.
The lease liability is initially measured at the present value of the lease payments that are unpaid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee, and the cost of any options that the company is reasonably certain to exercise, such as the exercise price under a purchase option, lease payments in an optional renewal period, or penalties for early termination of a lease.
The lease liability is measured at amortised cost using the effective interest method. It is reassessed at each financial period end to reflect lease modifications and any changes to the factors considered at initial measurement, as set out above. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
2
Critical accounting estimates and judgements
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
30
39
4
Intangible fixed assets
Software
Website
Total
£
£
£
Cost
At 31 December 2023
123,468
51,631
175,099
At 31 December 2024
123,468
51,631
175,099
Amortisation and impairment
At 31 December 2023
120,928
51,631
172,559
Charge for the year
1,361
-
1,361
At 31 December 2024
122,289
51,631
173,920
Carrying amount
At 31 December 2024
1,179
-
1,179
At 31 December 2023
2,540
-
2,540
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
5
Tangible fixed assets
Right-of-use leasehold property
Plant and equipment
Right-of-use other assets
Right-of-use motor vehicles
Total
£
£
£
£
£
Cost
At 1 January 2024
537,962
995,314
16,721
214,367
1,764,364
Additions
45,453
14,025
132,573
192,051
Disposals
(12,022)
(93,282)
(105,304)
At 31 December 2024
583,415
1,009,339
4,699
253,658
1,851,111
Accumulated depreciation and impairment
At 1 January 2024
233,275
970,285
12,055
144,720
1,360,335
Charge for the year
58,812
9,588
1,847
77,346
147,593
Eliminated on disposal
(12,022)
(93,282)
(105,304)
At 31 December 2024
292,087
979,873
1,880
128,784
1,402,624
Carrying amount
At 31 December 2024
291,328
29,466
2,819
124,874
448,487
At 31 December 2023
304,687
25,029
4,666
69,647
404,029
6
Stocks
2024
2023
£
£
Raw materials
363,658
333,179
Work in progress
15,701
20,316
Finished goods
335,163
432,099
714,522
785,594
7
Debtors
2024
2023
£
£
Trade debtors
727,221
334,349
Provision for bad and doubtful debts
(11,000)
(10,000)
716,221
324,349
Amounts owed by fellow group undertakings
13,104
23,118
Prepayments and accrued income
58,585
96,802
787,910
444,269
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
8
Creditors
Due within one year
Due after one year
2024
2023
2024
2023
Notes
£
£
£
£
Creditors
9
3,233,455
2,939,911
Taxation and social security
60,473
50,567
-
-
Lease liabilities
10
125,162
98,515
322,201
305,346
3,419,090
3,088,993
322,201
305,346
9
Creditors
2024
2023
£
£
Trade creditors
165,922
247,299
Amount owed to parent undertaking
2,409,319
1,952,183
Amounts owed to fellow group undertakings
78,645
100,534
Accruals and deferred income
579,569
639,895
3,233,455
2,939,911
10
Lease liabilities
2024
2023
Maturity analysis
£
£
Within one year
125,162
98,515
In two to five years
322,201
287,688
In over five years
-
17,658
Total undiscounted liabilities
447,363
403,861
Lease liabilities are classified based on the amounts that are expected to be settled within the next 12 months and after more than 12 months from the reporting date, as follows:
2024
2023
£
£
Current liabilities
125,162
98,515
Non-current liabilities
322,201
305,346
447,363
403,861
2024
2023
Amounts recognised in profit or loss include the following:
£
£
Interest on lease liabilities
17,430
22,358
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
11
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the company and movements thereon during the current and prior reporting period.
ACAs
Tax losses
Retirement benefit obligations
Total
£
£
£
£
Asset at 1 January 2023
(53,409)
(259,341)
(30)
(312,780)
Deferred tax movements in prior year
Charge/(credit) to profit or loss
8,946
(6,785)
(2,161)
Asset at 1 January 2024
(44,463)
(266,126)
(2,191)
(312,780)
Deferred tax movements in current year
Charge/(credit) to profit or loss
9,421
(11,612)
2,191
Asset at 31 December 2024
(35,042)
(277,738)
(312,780)
Deferred tax assets are expected to be recovered after more than one year.
12
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
49,808
66,180
The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.
13
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
6,500,002
6,500,002
6,500,002
6,500,002
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
14
Audit report information
As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:
The auditor's report is unqualified and includes the following:
Opinion
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
Senior Statutory Auditor:
James King
Statutory Auditor:
Pierce C A Limited
Date of audit report:
29 September 2025
15
Related party transactions
The company is exempt from disclosing certain related party transactions as they are with other companies that are wholly owned within the group.
During the year the company purchased goods from its ultimate parent company and a fellow group subsidiary at discounted rates. Total purchases made from these companies in the year were £1,448,933 (2023 - £532,773).
2024-12-312024-01-01J S PotterS EhrenreichN KinoryE GinnatfalsefalseCCH SoftwareiXBRL Review & Tag 2025.2028267932024-01-012024-12-31028267932024-12-3102826793core:IntangibleAssetsOtherThanGoodwill2024-12-3102826793core:IntangibleAssetsOtherThanGoodwill2023-12-3102826793core:ComputerSoftware2024-12-3102826793core:ComputerSoftware2023-12-31028267932023-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3102826793core:PlantMachinery2024-12-3102826793core:FurnitureFittings2024-12-3102826793core:MotorVehicles2024-12-3102826793core:ContinuingOperations2024-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3102826793core:PlantMachinery2023-12-3102826793core:FurnitureFittings2023-12-3102826793core:MotorVehicles2023-12-3102826793core:AcceleratedTaxDepreciationDeferredTax2022-12-3102826793core:TaxLossesCarry-forwardsDeferredTax2022-12-3102826793core:RetirementBenefitObligationsDeferredTax2022-12-31028267932022-12-3102826793core:AcceleratedTaxDepreciationDeferredTax2023-12-3102826793core:TaxLossesCarry-forwardsDeferredTax2023-12-3102826793core:RetirementBenefitObligationsDeferredTax2023-12-3102826793core:AcceleratedTaxDepreciationDeferredTax2024-12-3102826793core:TaxLossesCarry-forwardsDeferredTax2024-12-3102826793core:RetirementBenefitObligationsDeferredTax2024-12-3102826793core:BetweenOneFiveYears2023-12-3102826793core:CurrentFinancialInstruments2024-12-3102826793core:CurrentFinancialInstruments2023-12-3102826793core:Non-currentFinancialInstruments2024-12-3102826793core:Non-currentFinancialInstruments2023-12-3102826793core:ShareCapital2024-12-3102826793core:ShareCapital2023-12-3102826793core:RetainedEarningsAccumulatedLosses2024-12-3102826793core:RetainedEarningsAccumulatedLosses2023-12-3102826793bus:Director12024-01-012024-12-31028267932023-01-012023-12-3102826793core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-12-3102826793core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-12-3102826793core:ComputerSoftware2023-12-31028267932023-12-3102826793core:ComputerSoftware2024-01-012024-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3102826793core:PlantMachinery2023-12-3102826793core:FurnitureFittings2023-12-3102826793core:MotorVehicles2023-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-01-012024-12-3102826793core:PlantMachinery2024-01-012024-12-3102826793core:FurnitureFittings2024-01-012024-12-3102826793core:MotorVehicles2024-01-012024-12-3102826793core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3102826793core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3102826793core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3102826793core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3102826793bus:PrivateLimitedCompanyLtd2024-01-012024-12-3102826793bus:FRS1012024-01-012024-12-3102826793bus:Audited2024-01-012024-12-3102826793bus:Director22024-01-012024-12-3102826793bus:Director32024-01-012024-12-3102826793bus:Director42024-01-012024-12-3102826793bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3102826793bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP